<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:02:41Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5069541" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5069541</identifier><datestamp>2016-10-25</datestamp><setSpec>cpe</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Pediatr Endocrinol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin Pediatr Endocrinol</journal-id>
      <journal-id journal-id-type="publisher-id">CPE</journal-id>
      <journal-title-group>
        <journal-title>Clinical Pediatric Endocrinology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0918-5739</issn>
      <issn pub-type="epub">1347-7358</issn>
      <publisher>
        <publisher-name>The Japanese Society for Pediatric Endocrinology</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5069541</article-id>
      <article-id pub-id-type="pmcid">PMC5069541</article-id>
      <article-id pub-id-type="pmc-uid">5069541</article-id>
      <article-id pub-id-type="pmid">27780982</article-id>
      <article-id pub-id-type="publisher-id">2016-0006</article-id>
      <article-id pub-id-type="doi">10.1297/cpe.25.127</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A patient with pseudohypoaldosteronism type II complicated by congenital
hypopituitarism carrying a <italic>KLHL3</italic> mutation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mitani</surname>
            <given-names>Marie</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Furuichi</surname>
            <given-names>Munehiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Narumi</surname>
            <given-names>Satoshi</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hasegawa</surname>
            <given-names>Tomonobu</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chiga</surname>
            <given-names>Motoko</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Uchida</surname>
            <given-names>Shinichi</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sato</surname>
            <given-names>Seiji</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Pediatrics, Saitama City Hospital, Saitama,
Japan</aff>
        <aff id="aff2"><label>2</label>Department of Pediatrics, Keio University School of Medicine,
Tokyo, Japan</aff>
        <aff id="aff3"><label>3</label>Department of Nephrology, Tokyo Medical and Dental
University, Tokyo, Japan</aff>
      </contrib-group>
      <author-notes>
        <corresp>Corresponding author: Dr. Seiji Sato, Department of Pediatrics, Saitama City
Hospital, 2460 Mimuro, Midori-ku, Saitama-shi, Saitama 226-8522, Japan</corresp>
        <corresp>E-mail: <email xlink:href="hsp-shounika-b@city.saitama.lg.jp">hsp-shounika-b@city.saitama.lg.jp</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <volume>25</volume>
      <issue>4</issue>
      <fpage>127</fpage>
      <lpage>134</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>2</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>5</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>2016Â©The Japanese Society for Pediatric
Endocrinology</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p>
        </license>
      </permissions>
      <abstract>
        <title>Abstract.</title>
        <p>Pseudohypoaldosteronism type II (PHA II) is a renal tubular disease that causes
hyperkalemia, hypertension, and metabolic acidosis. Mutations in four genes
(<italic>WNK4</italic>, <italic>WNK1</italic>, <italic>KLHL3</italic>, and
<italic>CUL3</italic>) are known to cause PHA II. We report a patient with PHA II
carrying a <italic>KLHL3</italic> mutation, who also had congenital hypopituitarism. The
patient, a 3-yr-old boy, experienced loss of consciousness at age 10 mo. He exhibited
growth failure, hypertension, hyperkalemia, and metabolic acidosis. We diagnosed him as
having PHA II because he had low plasma renin activity with normal plasma aldosterone
level and a low transtubular potassium gradient. Further investigations revealed defective
secretion of GH and gonadotropins and anterior pituitary gland hypoplasia. Genetic
analyses revealed a previously known heterozygous <italic>KLHL3</italic> mutation
(p.Leu387Pro), but no mutation was detected in 27 genes associated with congenital
hypopituitarism. He was treated with sodium restriction and recombinant human GH, which
normalized growth velocity. This is the first report of a molecularly confirmed patient
with PHA II complicated by congenital hypopituitarism. We speculate that both GH
deficiency and metabolic acidosis contributed to growth failure. Endocrinological
investigations will help to individualize the treatment of patients with PHA II presenting
with growth failure.</p>
      </abstract>
      <kwd-group>
        <kwd>pseudohypoaldosteronism type II</kwd>
        <kwd>congenital hypopituitarism</kwd>
        <kwd>
          <italic>KLHL3</italic>
        </kwd>
        <kwd>growth failure</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Pseudohypoaldosteronism (PHA) is a rare renal tubular disease that can be divided into two
types based on their pathogenesis. PHA type I (PHA I) is caused by abnormalities in the
aldosterone receptor or epithelial sodium channel and is inherited in an autosomal dominant
or recessive manner, respectively. PHA I is clinically characterized by renal salt wasting
and decreased response of the aldosterone receptor or epithelial sodium channel to
aldosterone. PHA type II (PHA II, also referred to as Gordon syndrome(<xref rid="r1" ref-type="bibr">1</xref>)) is a heterogeneous syndrome inherited in an autosomal dominant or
recessive manner. The best-characterized pathogenesis of PHA II is associated with increased
membrane expression of the thiazide-sensitive NaCl cotransporter (NCC) in the distal
convoluted tubules, resulting in excessive sodium resorption. Excretion of potassium and
hydrogen is decreased because it is coupled with sodium resorption. As a result, patients
with PHA II show early-onset hypertension, hyperkalemia, and metabolic acidosis. Plasma
renin levels are suppressed and aldosterone levels are variable but are relatively low given
the degree of hyperkalemia. Other clinical manifestations of PHA II include growth failure,
muscle weakness, periodic paralysis, skeletal abnormalities, urinary calculus, and
psychomotor retardation. Electrolyte abnormalities and hypertension can be treated with
thiazide.</p>
      <p>Recently, the molecular pathogenesis of PHA II was partly elucidated. In 2001, Wilson
<italic>et al</italic>. conducted positional cloning analyses of PHA II kindreds and
identified mutations in the WNK family kinase genes (<italic>WNK1</italic> and
<italic>WNK4</italic>). The two kinases are involved in the plasma membrane expression of
NCC (<xref rid="r2" ref-type="bibr">2</xref>). In 2012, Boyden <italic>et al</italic>.
performed whole exome sequencing in patients with PHA II, identifying two additional
causative genes (<italic>KLHL3</italic> and <italic>CUL3</italic>) (<xref rid="r3" ref-type="bibr">3</xref>). The KLHL3-CUL3 complex acts as a negative regulator of WNK kinases
through ubiquitination of the two kinases. Thus, mutations in <italic>KLHL3</italic> or
<italic>CUL3</italic> are thought to increase the membrane expression of NCC via increased
WNK kinases (<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>). Among the 52 PHA II kindreds, 24 showed <italic>KLHL3</italic> mutations (eight
were autosomal recessive inheritance, 16 were autosomal dominant inheritance), 17 showed
<italic>CUL3</italic> mutations, five showed <italic>WNK4</italic> mutations, and two
showed <italic>WNK1</italic> mutations (<xref rid="r3" ref-type="bibr">3</xref>).</p>
      <p>Here, we report a patient with PHA II complicated by congenital hypopituitarism carrying a
<italic>KLHL3</italic> mutation. The patient exhibited growth failure. Two possible
factors, PHA II and congenital hypopituitarism, were considered as the cause(s) of the
growth failure.</p>
    </sec>
    <sec id="s2">
      <title>Case Report</title>
      <p>The proband, a 3-yr-old boy, was the second child of healthy nonconsanguineous Japanese
parents. The course of pregnancy and delivery were uneventful. He was born at gestational
age 39 wk with a birth length of 51 cm (+1.0 SD) and weight of 2918 g (â0.2 SD). At age 10
mo, he experienced loss of consciousness after a 15-h fasting period and was brought to our
hospital. On physical examination, short stature (68.0 cm; â2.0 SD) and normal weight (8.6
kg; â0.6 SD) were noted. He was drowsy but moved his extremities in response to verbal or
physical stimulation. He had elevated blood pressure (110/55 mmHg; age-matched reference
ranges 80â105/34â61) with a normal heart rate. His testes were in the scrotum and his
testicular volume was 2 cm<sup>3</sup> per testis. His stretched penile length was 3.0 cm
(â0.8 SD). He had no abnormalities in deciduous teeth. Routine blood examination revealed a
high serum potassium level (6.6 mM), high serum chloride level (107 mM), normal plasma
glucose level (77 mg/dL), and an elevated beta-hydroxybutyrate level (1.6 mM; reference
ranges 0â0.074). Mild metabolic acidosis was observed by vein blood gas analysis (pH 7.34,
estimated bicarbonate level 14.8 mM). Bone age was not evaluated. He was treated with
intravenous half saline including glucose, and his consciousness was normal 3 h after fluid
therapy. Although hyperkalemia and hyperchloremia gradually improved, hypertension and
metabolic acidosis (estimated bicarbonate levels 14.6â16.0 mM) were sustained through eight
days after admission. Hyperkalemia reoccurred at home after discharge and was sustained
until the introduction of sodium-intake restriction.</p>
      <p>To clarify the etiology of metabolic acidosis, transient hyperkalemia, and hypertension, we
conducted a series of renal function tests. Ultrasonography of the kidneys showed no
anatomical lesions or calcification. Plasma renin activity was low (0.6 ng/mL/h; reference
1.0â3.2) with normal plasma aldosterone level (66 pg/mL; reference 66â218). Transtubular
potassium gradient was low (4.5; reference &gt;5.0), indicating that renal potassium
excretion was decreased. Based on these clinical data, we diagnosed him with PHA II.</p>
      <p>When we reviewed the growth record of the patient, we noted slow decreases in length/height
and weight from age 8 mo. Serum IGF1 levels were very low (&lt; 4 ng/mL; age-matched
reference 11â149 (<xref rid="r8" ref-type="bibr">8</xref>)). Provocation tests for GH
release revealed low GH responses to insulin, arginine, and glucagon (peak GH 0.9, 1.7, and
2.1 ng/mL, respectively). He also had a poor gonadotropin response to GnRH (peak LH 0.39
mIU/L, peak FSH 0.98 mIU/L). Responses of TSH, ACTH, and prolactin were not defective.
Cranial magnetic resonance imaging revealed hypoplasia of the anterior pituitary gland. We
diagnosed him with congenital hypopituitarism.</p>
      <p>He was treated with sodium restriction (sodium intake 600 mg/day) and recombinant human GH
replacement from age 14 mo. His height SD score increased gradually (93.9 cm; â0.5 SD at age
40 mo) (<xref ref-type="fig" rid="fig_001">Fig. 1</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>Growth chart of the patient. Prior to admission because of an episode of loss of
consciousness (age 10 mo), the patient showed growth failure beginning at age 8 mo.
After the initiation of treatment by GH replacement and sodium restriction at age 14
mo, he showed catch-up growth.</p></caption><graphic xlink:href="cpe-25-127-g001"/></fig>), which coincided with elevation in serum IGF1 levels. Maximum growth velocity was
achieved after age 20 mo when metabolic acidosis was alleviated (<xref ref-type="fig" rid="fig_002">Fig. 2</xref><fig orientation="portrait" fig-type="figure" id="fig_002" position="float"><label>Fig. 2.</label><caption><p>Chronological changes in growth velocity, IGF1 levels, and bicarbonate levels. Shaded
areas indicate age-matched reference ranges. The recovery of growth velocity coincided
with the increase in serum IGF1 levels immediately after beginning GH replacement.
Metabolic acidosis was alleviated from age 20 mo. The bicarbonate level became normal
by age 30 mo.</p></caption><graphic xlink:href="cpe-25-127-g002"/></fig>). Hypertension was improved by age 21 mo. Metabolic acidosis was improved by age 30
mo (<xref ref-type="fig" rid="fig_002">Fig. 2</xref>), although mild hyperkalemia (5.1â6.0
mM) was sustained. We did not use thiazide throughout the course because metabolic acidosis
and hyperkalemia were mild. Loss of consciousness did not reoccur after the first admission.
Psychomotor development has remained intact.</p>
    </sec>
    <sec sec-type="materials|methods" id="s3">
      <title>Materials and Methods</title>
      <sec>
        <title>Genetic analyses</title>
        <p>The genetic study was approved by the ethics committees of Keio University School of
Medicine and Tokyo Medical and Dental University. Written informed consent for genetic
analyses was obtained from the parents of the proband. Genomic DNA samples were extracted
from the peripheral blood of the proband, his mother, and elder brother using standard
techniques. Four causative genes for PHA II (<italic>WNK1</italic>, <italic>WNK4</italic>,
<italic>KLHL3</italic>, and <italic>CUL3</italic>) were analyzed by PCR-based direct
sequencing. Twenty-seven genes associated with hypopituitarism (<italic>GH1</italic>,
<italic>GHRH</italic>, <italic>GHRHR</italic>, <italic>GHSR</italic>,
<italic>GLI2</italic>, <italic>HESX1</italic>, <italic>LHX4</italic>,
<italic>OTX2</italic>, <italic>PAXS</italic>, <italic>POU1F1</italic>,
<italic>PROP1</italic>, <italic>SIX3</italic>, <italic>TBX19</italic>,
<italic>CHD7</italic>, <italic>FGFR1</italic>, <italic>FSH8</italic>,
<italic>TAC3</italic>, <italic>TACR3</italic>, <italic>GNRH1</italic>,
<italic>GNRHR</italic>, <italic>KAL1</italic>, <italic>KISS1</italic>,
<italic>KISS1R</italic>, <italic>LHB</italic>, <italic>PROK2</italic>,
<italic>PROKR2</italic>, <italic>SOX2</italic>) were analyzed by next-generation
targeted sequencing as previously described (<xref rid="r9" ref-type="bibr">9</xref>).</p>
      </sec>
      <sec>
        <title>RNA expression analysis of <bold><italic>KLHL3</italic></bold></title>
        <p>Human pituitary gland cDNA (Human Pituitary Gland QUICK-Clone cDNA) was purchased from
TaKaRa Biotechnology (Shiga, Japan). Human thymus RNA was purchased from Agilent
Technologies (Santa Clara, CA, USA), and was reverse-transcribed into cDNA using the
SuperScript III First-Strand Synthesis System (Life Technologies, Carlsbad, CA, USA) and
an oligo-dT primer. Primer pairs each specific for <italic>KLHL3</italic> cDNA (forward
5â²-AGATGTACACACCTGCACTGACCTT-3â², reverse 5â²-GACATGTTCCATCAGCTTTGC-CATG-3â²) and
<italic>GAPDH</italic> cDNA (TaKaRa, HA067812) were used in PCR to estimate the RNA
expression levels of the two genes in the pituitary gland and thymus. Thirty-five cycles
of PCR amplification were performed using ExTaq HS (TaKaRa) according to the
manufacturerâs instructions. The PCR products were electrophoresed in a 1.2% agarose gel
containing ethidium bromide. We detected the band using a UV transformer illuminator.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s4">
      <title>Results</title>
      <sec>
        <title>Genetic analyses</title>
        <p>Clinical diagnosis of PHA II and congenital hypopituitarism prompted us to perform
genetic analyses to clarify the genetic bases of the two diseases. PCR-based direct
sequencing of PHA II-associated genes revealed a heterozygous <italic>KLHL3</italic>
mutation (p.Leu387Pro), which has previously been reported in patients with PHA II (<xref rid="r3" ref-type="bibr">3</xref>). Family analyses unexpectedly demonstrated that the
mother and elder brother carried identical mutations. Blood examination of the two family
member showed that both had hyperkalemia (5.9 mM in both). Metabolic acidosis was observed
only in the brother (pH 7.31, estimated bicarbonate level 21.2 mM). The mother had leg
length discrepancy and persistence of deciduous teeth. The mother and brother had neither
hypertension nor short stature (mother: blood pressure 110/54 mmHg and height 163 cm at
age 34 yr, brother: blood pressure 79/27 mmHg and height 97.8 cm; +0.9 SD at age 3 yr). We
further analyzed 27 genes associated with the hypopituitarism for the proband, but no
disease-causing variation was found.</p>
      </sec>
      <sec>
        <title>RNA expression analysis of <bold><italic>KLHL3</italic></bold></title>
        <p>RT-PCR analysis showed that <italic>KLHL3</italic> mRNA was expressed in the pituitary
gland, although the expression level was low (<xref ref-type="fig" rid="fig_003">Fig.
3</xref><fig orientation="portrait" fig-type="figure" id="fig_003" position="float"><label>Fig. 3.</label><caption><p>RT-PCR analysis of <italic>KLHL3</italic>. <italic>KLHL3</italic> mRNA is expressed
in the human pituitary gland, although the level of expression was low. A
thymus-derived sample was used as a control.</p></caption><graphic xlink:href="cpe-25-127-g003"/></fig>).</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s5">
      <title>Discussion</title>
      <p>We described a patient with PHA II carrying <italic>KLHL3</italic> mutation, who showed
growth failure at first presentation. Endocrinological investigations revealed congenital
hypopituitarism affecting the secretion of GH and gonadotropins. Both GH deficiency and
metabolic acidosis was suspected to be responsible for the growth failure. However, the
recovery of growth velocity coincided with the increase in serum IGF1 levels, indicating
that his growth was at least in part affected by GH deficiency.</p>
      <p>Growth failure is a PHA II-associated symptom, but the frequency has not been investigated
in a structured manner. We reviewed 42 patients with PHA II whose growth records were
described in the literature and found that 16 (38%) had short stature (<xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1</label><caption><title>Sixteen patients with pseudohypoaldosteronism type II who had short
stature</title></caption><graphic xlink:href="cpe-25-127-t001"/></table-wrap>). Six of 16 patients experienced catch-up growth after treatment with
thiazide.</p>
      <p>The cause(s) of growth failure in PHA II are not fully understood, although metabolic
acidosis is the most plausible explanation (<xref rid="r10" ref-type="bibr">10</xref>).
Boyden <italic>et al</italic>. reported that patients with PHA II with <italic>CUL3</italic>
mutations generally showed more severe acidosis and hyperkalemia and a greater likelihood of
growth failure than patients with mutations in <italic>WNK1</italic>, <italic>WNK4</italic>,
and <italic>KLHL3</italic> (<xref rid="r3" ref-type="bibr">3</xref>). McSherry <italic>et
al</italic>. reported that growth failure associated with renal tubular acidosis in
children was reversible upon alkali treatment (<xref rid="r11" ref-type="bibr">11</xref>).
The mechanisms of acidosis causing growth failure have been elucidated in some reports.
Brungger <italic>et al</italic>. reported that the IGF1 response to GH administration was
significantly blunted during acidosis, while the GH response to GH releasing factor
administration was significantly enhanced (<xref rid="r12" ref-type="bibr">12</xref>). Mitch
<italic>et al</italic>. reported that metabolic acidosis stimulated muscle protein
degradation (<xref rid="r13" ref-type="bibr">13</xref>). A similar mechanism may explain the
growth failure observed in patients with PHA II. In the present case, the recovery of growth
velocity coincided with the increase in serum IGF1 levels, which began immediately after
beginning GH replacement, suggesting that his growth was affected by GH deficiency. However,
maximum growth velocity was achieved after age 20 months when metabolic acidosis was
alleviated. This indicates that correcting the acidosis improved the actions of anabolic
hormones and further increased his growth velocity.</p>
      <p>The mother and brother of the proband did not have short stature, although they carried the
identical <italic>KLHL3</italic> mutation (p.Leu387Pro). It is clear that the complication
of congenital hypopituitarism of the proband caused the differences in height among the
family members. Regarding the PHA II phenotypes (e.g. hypertension, metabolic acidosis, and
hyperkalemia), it is unclear which factor(s) were responsible for the differences. Farfel
<italic>et al</italic>. observed no significant difference in severity of low IGF1,
hyperkalemia, metabolic acidosis, and hypercalciuria in affected family members with short
stature and with normal stature (<xref rid="r14" ref-type="bibr">14</xref>). Gordon
<italic>et al</italic>. found that the difference in sodium intake appeared to cause the
phenotypic differences, particularly hypertension (<xref rid="r15" ref-type="bibr">15</xref>).</p>
      <p>In the present case, the patient lost consciousness on first admission. This may have been
because of hypoglycemia, which was followed by a 15-h fasting period, although plasma
glucose level was normal upon admission. Considering that severe hypoglycemia stimulates the
secretion of counterregulatory hormones, normal plasma glucose levels at admission do not
exclude the possibility of hypoglycemia as the cause of loss of consciousness.</p>
      <p>This is the first case report of the coexistence of PHA II and congenital hypopituitarism.
In the original report of the identification of the human <italic>KLHL</italic> gene, the
highest <italic>KLHL3</italic> mRNA expression was observed in the pituitary gland and
cerebellum (<xref rid="r16" ref-type="bibr">16</xref>). Using RT-PCR, we confirmed the
expression of <italic>KLHL3</italic> mRNA in the pituitary gland. The function of KLHL3 in
the pituitary gland is unknown. Considering that KLHL2 is an actin-binding protein affecting
cytoskeleton dynamics in neurons, it is possible that KLHL3 also affects cell motility where
it is expressed (<xref rid="r16" ref-type="bibr">16</xref>). However, <italic>KLHL3</italic>
mRNA expression was very low in the pituitary gland, indicating that <italic>KLHL3</italic>
mutations did not cause hypopituitarism. Additionally, no other <italic>KLHL3</italic>
mutation carriers reported so far (including the mother and brother of the proband in this
report) had hypopituitarism. Thus, we speculate that the <italic>KLHL3</italic> mutation and
congenital hypopituitarism were independent occurrences. The presence of additional
factor(s), such as genetic, epigenetic, and environmental factors, may be required to cause
aberrant development of the anterior pituitary lobe.</p>
      <p>In conclusion, we described a patient with PHA II carrying <italic>KLHL3</italic> mutation,
who showed growth failure and congenital hypopituitarism. Our case exemplifies the
importance of endocrinological investigations in patients with PHA II with growth
failure.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Dr. Midori Awazu for clinical advice and all colleagues of Saitama City Hospital,
Kawasaki Municipal Hospital and Shizuoka City Shimizu Hospital for helpful discussions. This
study was supported by a Health and Labour Sciences Research Grant for Research on Applying
Health Technology (Jitsuyoka (Nanbyo) â Ippan-014) and a grant from the Foundation for
Growth Science, Japan.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="r1">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Gordon</surname><given-names>RD</given-names></name></person-group>. <article-title>Syndrome of hypertension and hyperkalemia with normal
glomerular filtration rate</article-title>.
<source>Hypertension</source><year>1986</year>;<volume>8</volume>:
<fpage>93</fpage>â<lpage>102</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.HYP.8.2.93</pub-id><?supplied-pmid 3002982?><pub-id pub-id-type="pmid">3002982</pub-id></mixed-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Wilson</surname><given-names>FH</given-names></name><name><surname>Disse-NicodÃ¨me</surname><given-names>S</given-names></name><name><surname>Choate</surname><given-names>KA</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Nelson-Williams</surname><given-names>C</given-names></name><name><surname>Desitter</surname><given-names>I</given-names></name><etal>et al</etal></person-group>. <article-title>Human hypertension caused by mutations in WNK
kinases</article-title>. <source>Science</source><year>2001</year>;<volume>293</volume>:
<fpage>1107</fpage>â<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1062844</pub-id><?supplied-pmid 11498583?><pub-id pub-id-type="pmid">11498583</pub-id></mixed-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Boyden</surname><given-names>LM</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Choate</surname><given-names>KA</given-names></name><name><surname>Nelson-Williams</surname><given-names>CJ</given-names></name><name><surname>Farhi</surname><given-names>A</given-names></name><name><surname>Toka</surname><given-names>HR</given-names></name><etal>et al</etal></person-group>. <article-title>Mutations in kelch-like 3 and cullin 3 cause hypertension
and electrolyte abnormalities</article-title>.
<source>Nature</source><year>2012</year>;<volume>482</volume>:
<fpage>98</fpage>â<lpage>102</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature10814</pub-id><?supplied-pmid 22266938?><pub-id pub-id-type="pmid">22266938</pub-id></mixed-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Kahle</surname><given-names>KT</given-names></name><name><surname>Wilson</surname><given-names>FH</given-names></name><name><surname>Leng</surname><given-names>Q</given-names></name><name><surname>Lalioti</surname><given-names>MD</given-names></name><name><surname>OâConnell</surname><given-names>AD</given-names></name><name><surname>Dong</surname><given-names>K</given-names></name><etal>et al</etal></person-group>. <article-title>WNK4 regulates the balance between renal NaCl reabsorption
and K+ secretion</article-title>. <source>Nat
Genet</source><year>2003</year>;<volume>35</volume>:
<fpage>372</fpage>â<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ng1271</pub-id><?supplied-pmid 14608358?><pub-id pub-id-type="pmid">14608358</pub-id></mixed-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Wakabayashi</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Araki</surname><given-names>Y</given-names></name><name><surname>Sohara</surname><given-names>E</given-names></name><name><surname>Rai</surname><given-names>T</given-names></name><etal>et al</etal></person-group>. <article-title>Decrease of WNK4 ubiquitination by disease-causing
mutations of KLHL3 through different molecular mechanisms</article-title>.
<source>Biochem Biophys Res Commun</source><year>2013</year>;<volume>439</volume>:
<fpage>30</fpage>â<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2013.08.035</pub-id><?supplied-pmid 23962426?><pub-id pub-id-type="pmid">23962426</pub-id></mixed-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Wakabayashi</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Isobe</surname><given-names>K</given-names></name><name><surname>Sohara</surname><given-names>E</given-names></name><name><surname>Susa</surname><given-names>K</given-names></name><name><surname>Araki</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>. <article-title>Impaired KLHL3-mediated ubiquitination of WNK4 causes
human hypertension</article-title>. <source>Cell
Reports</source><year>2013</year>;<volume>3</volume>:
<fpage>858</fpage>â<lpage>68</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2013.02.024</pub-id><?supplied-pmid 23453970?><pub-id pub-id-type="pmid">23453970</pub-id></mixed-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Uchida</surname><given-names>S</given-names></name><name><surname>Sohara</surname><given-names>E</given-names></name><name><surname>Rai</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name></person-group>. <article-title>Regulation of with-no-lysine kinase signaling by
Kelch-like proteins</article-title>. <source>Biol
Cell</source><year>2014</year>;<volume>106</volume>:
<fpage>45</fpage>â<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1111/boc.201300069</pub-id><?supplied-pmid 24313290?><pub-id pub-id-type="pmid">24313290</pub-id></mixed-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Isojima</surname><given-names>T</given-names></name><name><surname>Shimatsu</surname><given-names>A</given-names></name><name><surname>Yokoya</surname><given-names>S</given-names></name><name><surname>Chihara</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Hizuka</surname><given-names>N</given-names></name><etal>et al</etal></person-group>. <article-title>Standardized centile curves and reference intervals of
serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using
the LMS method</article-title>. <source>Endocr
J</source><year>2012</year>;<volume>59</volume>: <fpage>771</fpage>â<lpage>80</lpage>.
doi: <pub-id pub-id-type="doi">10.1507/endocrj.EJ12-0110</pub-id><?supplied-pmid 22673406?><pub-id pub-id-type="pmid">22673406</pub-id></mixed-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Asakura</surname><given-names>Y</given-names></name><name><surname>Muroya</surname><given-names>K</given-names></name><name><surname>Hanakawa</surname><given-names>J</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Aida</surname><given-names>N</given-names></name><name><surname>Narumi</surname><given-names>S</given-names></name><etal>et al</etal></person-group>. <article-title>Combined pituitary hormone deficiency with unique
pituitary dysplasia and morning glory syndrome related to a heterozygous PROKR2
mutation</article-title>. <source>Clin Pediatr
Endocrinol</source><year>2015</year>;<volume>24</volume>:
<fpage>27</fpage>â<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1297/cpe.24.27</pub-id><?supplied-pmid 25678757?><pub-id pub-id-type="pmid">25678757</pub-id></mixed-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Spitzer</surname><given-names>A</given-names></name><name><surname>Edelmann</surname><given-names>CM</given-names><suffix>Jr</suffix></name><name><surname>Goldberg</surname><given-names>LD</given-names></name><name><surname>Henneman</surname><given-names>PH</given-names></name></person-group>. <article-title>Short stature, hyperkalemia and acidosis: A defect in
renal transport of potassium</article-title>. <source>Kidney
Int</source><year>1973</year>;<volume>3</volume>: <fpage>251</fpage>â<lpage>7</lpage>.
doi: <pub-id pub-id-type="doi">10.1038/ki.1973.38</pub-id><?supplied-pmid 4792041?><pub-id pub-id-type="pmid">4792041</pub-id></mixed-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>McSherry</surname><given-names>E</given-names></name><name><surname>Morris</surname><given-names>RC</given-names><suffix>Jr</suffix></name></person-group>. <source>J Clin Invest</source><year>1978</year>;<volume>61</volume>:
<fpage>509</fpage>â<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI108962</pub-id><?supplied-pmid 621287?><pub-id pub-id-type="pmid">621287</pub-id></mixed-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>BrÃ¼ngger</surname><given-names>M</given-names></name><name><surname>Hulter</surname><given-names>HN</given-names></name><name><surname>Krapf</surname><given-names>R</given-names></name></person-group>. <article-title>Effect of chronic metabolic acidosis on the growth
hormone/IGF-1 endocrine axis: new cause of growth hormone insensitivity in
humans</article-title>. <source>Kidney
Int</source><year>1997</year>;<volume>51</volume>: <fpage>216</fpage>â<lpage>21</lpage>.
doi: <pub-id pub-id-type="doi">10.1038/ki.1997.26</pub-id><?supplied-pmid 8995736?><pub-id pub-id-type="pmid">8995736</pub-id></mixed-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Mitch</surname><given-names>WE</given-names></name><name><surname>Medina</surname><given-names>R</given-names></name><name><surname>Grieber</surname><given-names>S</given-names></name><name><surname>May</surname><given-names>RC</given-names></name><name><surname>England</surname><given-names>BK</given-names></name><name><surname>Price</surname><given-names>SR</given-names></name><etal>et al</etal></person-group>. <article-title>Metabolic acidosis stimulates muscle protein degradation
by activating the adenosine triphosphate-dependent pathway involving ubiquitin and
proteasomes</article-title>. <source>J Clin
Invest</source><year>1994</year>;<volume>93</volume>:
<fpage>2127</fpage>â<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI117208</pub-id><?supplied-pmid 8182144?><pub-id pub-id-type="pmid">8182144</pub-id></mixed-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Farfel</surname><given-names>A</given-names></name><name><surname>Mayan</surname><given-names>H</given-names></name><name><surname>Melnikov</surname><given-names>S</given-names></name><name><surname>Holtzman</surname><given-names>EJ</given-names></name><name><surname>Pinhas-Hamiel</surname><given-names>O</given-names></name><name><surname>Farfel</surname><given-names>Z</given-names></name></person-group>. <article-title>Effect of age and affection status on blood pressure,
serum potassium and stature in familial hyperkalaemia and hypertension</article-title>.
<source>Nephrol Dial Transplant</source><year>2011</year>;<volume>26</volume>:
<fpage>1547</fpage>â<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ndt/gfq612</pub-id><?supplied-pmid 20956807?><pub-id pub-id-type="pmid">20956807</pub-id></mixed-citation>
      </ref>
      <ref id="r15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Gordon</surname><given-names>RD</given-names></name><name><surname>Ravenscroft</surname><given-names>PJ</given-names></name><name><surname>Klemm</surname><given-names>SA</given-names></name><name><surname>Tunny</surname><given-names>TJ</given-names></name><name><surname>Hamlet</surname><given-names>SM</given-names></name></person-group>. <article-title>A new Australian kindred with the syndrome of hypertension
and hyperkalaemia has dysregulation of atrial natriuretic factor</article-title>.
<source>J Hypertens Suppl</source><year>1988</year>;<volume>6</volume>:
<fpage>S323</fpage>â<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00004872-198812040-00100</pub-id><?supplied-pmid 2977171?><pub-id pub-id-type="pmid">2977171</pub-id></mixed-citation>
      </ref>
      <ref id="r16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Lai</surname><given-names>F</given-names></name><name><surname>Orelli</surname><given-names>BJ</given-names></name><name><surname>Till</surname><given-names>BG</given-names></name><name><surname>Godley</surname><given-names>LA</given-names></name><name><surname>Fernald</surname><given-names>AA</given-names></name><name><surname>Pamintuan</surname><given-names>L</given-names></name><etal>et al</etal></person-group>. <article-title>Molecular characterization of KLHL3, a human homologue of
the Drosophila kelch gene</article-title>.
<source>Genomics</source><year>2000</year>;<volume>66</volume>:
<fpage>65</fpage>â<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1006/geno.2000.6181</pub-id><?supplied-pmid 10843806?><pub-id pub-id-type="pmid">10843806</pub-id></mixed-citation>
      </ref>
      <ref id="r17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Osawa</surname><given-names>M</given-names></name><name><surname>Ogura</surname><given-names>Y</given-names></name><name><surname>Isobe</surname><given-names>K</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name><name><surname>Nonoyama</surname><given-names>S</given-names></name><name><surname>Kawaguchi</surname><given-names>H</given-names></name></person-group>. <article-title>CUL3 gene analysis enables early intervention for
pediatric pseudohypoaldosteronism type II in infancy</article-title>. <source>Pediatr
Nephrol</source><year>2013</year>;<volume>28</volume>:
<fpage>1881</fpage>â<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00467-013-2496-6</pub-id><?supplied-pmid 23689903?><pub-id pub-id-type="pmid">23689903</pub-id></mixed-citation>
      </ref>
      <ref id="r18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Koshida</surname><given-names>S</given-names></name></person-group>
<article-title>A case of renal tublar acidosis type IV</article-title>.
<source>Japanese Journal of Pediatrics</source><year>2001</year>;<volume>54</volume>:
<fpage>1473</fpage>â<lpage>7</lpage><comment>(in
Japanese)</comment>.</mixed-citation>
      </ref>
      <ref id="r19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Sauder</surname><given-names>SE</given-names></name><name><surname>Kelch</surname><given-names>RP</given-names></name><name><surname>Grekin</surname><given-names>RJ</given-names></name><name><surname>Kelsch</surname><given-names>RC</given-names></name></person-group>. <article-title>Suppression of plasma renin activity in a boy with chronic
hyperkalemia</article-title>. <source>Am J Dis
Child</source><year>1987</year>;<volume>141</volume>:
<fpage>922</fpage>â<lpage>7</lpage>. <?supplied-pmid 3307388?><pub-id pub-id-type="pmid">3307388</pub-id></mixed-citation>
      </ref>
      <ref id="r20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Wayne</surname><given-names>VS</given-names></name><name><surname>Stockigt</surname><given-names>JR</given-names></name><name><surname>Jennings</surname><given-names>GL</given-names></name></person-group>. <article-title>Treatment of mineralocorticoid-resistant renal
hyperkalemia with hypertension (type II pseudohypoaldosteronism)</article-title>.
<source>Aust N Z J Med</source><year>1986</year>;<volume>16</volume>:
<fpage>221</fpage>â<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1445-5994.1986.tb01154.x</pub-id><?supplied-pmid 3463275?><pub-id pub-id-type="pmid">3463275</pub-id></mixed-citation>
      </ref>
      <ref id="r21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Gordon</surname><given-names>RD</given-names></name><name><surname>Geddes</surname><given-names>RA</given-names></name><name><surname>Pawsey</surname><given-names>CG</given-names></name><name><surname>OâHalloran</surname><given-names>MW</given-names></name></person-group>. <article-title>Hypertension and severe hyperkalaemia associated with
suppression of renin and aldosterone and completely reversed by dietary sodium
restriction</article-title>. <source>Australas Ann
Med</source><year>1970</year>;<volume>19</volume>: <fpage>287</fpage>â<lpage>94</lpage>.
<?supplied-pmid 5490655?><pub-id pub-id-type="pmid">5490655</pub-id></mixed-citation>
      </ref>
      <ref id="r22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>RodrÃ­guez-Soriano</surname><given-names>J</given-names></name><name><surname>Vallo</surname><given-names>A</given-names></name><name><surname>DomÃ­nguez</surname><given-names>MJ</given-names></name></person-group>. <article-title>âChloride-shuntâ syndrome: an overlooked cause of renal
hypercalciuria</article-title>. <source>Pediatr
Nephrol</source><year>1989</year>;<volume>3</volume>:
<fpage>113</fpage>â<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF00852890</pub-id><?supplied-pmid 2534969?><pub-id pub-id-type="pmid">2534969</pub-id></mixed-citation>
      </ref>
      <ref id="r23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Weinstein</surname><given-names>SF</given-names></name><name><surname>Allan</surname><given-names>DM</given-names></name><name><surname>Mendoza</surname><given-names>SA</given-names></name></person-group>. <article-title>Hyperkalemia, acidosis, and short stature associated with
a defect in renal potassium excretion</article-title>. <source>J
Pediatr</source><year>1974</year>;<volume>85</volume>:
<fpage>355</fpage>â<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0022-3476(74)80115-0</pub-id><?supplied-pmid 4431495?><pub-id pub-id-type="pmid">4431495</pub-id></mixed-citation>
      </ref>
      <ref id="r24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Iitaka</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>N</given-names></name><name><surname>Asakura</surname><given-names>A</given-names></name><name><surname>Kasai</surname><given-names>N</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name></person-group>
<article-title>Familial hyperkalemia, metabolic acidosis and short
stature with normal renin and aldosterone levels</article-title>. <source>Int J Pediatr
Nephrol</source><year>1980</year>;<volume>1</volume>:
<fpage>242</fpage>â<lpage>5</lpage>.</mixed-citation>
      </ref>
      <ref id="r25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Sanjad</surname><given-names>SA</given-names></name><name><surname>Mansour</surname><given-names>FM</given-names></name><name><surname>Hernandez</surname><given-names>RH</given-names></name><name><surname>Hill</surname><given-names>LL</given-names></name></person-group>. <article-title>Severe hypertension, hyperkalemia, and renal tubular
acidosis responding to dietary sodium restriction</article-title>.
<source>Pediatrics</source><year>1982</year>;<volume>69</volume>:
<fpage>317</fpage>â<lpage>24</lpage>. <?supplied-pmid 7063287?><pub-id pub-id-type="pmid">7063287</pub-id></mixed-citation>
      </ref>
      <ref id="r26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Licht</surname><given-names>JH</given-names></name><name><surname>Amundson</surname><given-names>D</given-names></name><name><surname>Hsueh</surname><given-names>WA</given-names></name><name><surname>Lombardo</surname><given-names>JV</given-names></name></person-group>. <article-title>Familiar hyperkalaemic acidosis</article-title>. <source>Q
J Med</source><year>1985</year>;<volume>54</volume>:
<fpage>161</fpage>â<lpage>76</lpage>. <?supplied-pmid 3885297?><pub-id pub-id-type="pmid">3885297</pub-id></mixed-citation>
      </ref>
      <ref id="r27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Gordon</surname><given-names>RD</given-names></name><name><surname>Hodsman</surname><given-names>GP</given-names></name></person-group>. <article-title>The syndrome of hypertension and hyperkalaemia without
renal failure: long term correction by thiazide diuretic</article-title>. <source>Scott
Med J</source><year>1986</year>;<volume>31</volume>: <fpage>43</fpage>â<lpage>4</lpage>.
<?supplied-pmid 3961473?><pub-id pub-id-type="pmid">3961473</pub-id></mixed-citation>
      </ref>
      <ref id="r28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group><name><surname>Bravo</surname><given-names>E</given-names></name><name><surname>Textor</surname><given-names>S</given-names></name><name><surname>Mujais</surname><given-names>S</given-names></name><name><surname>Cotton</surname><given-names>D</given-names></name></person-group>
<article-title>Chronic hyperkalemia in siblings associated with enhanced
renal chroride absorption</article-title><comment>[Abstract]</comment>
<source>Clin
Res</source><year>1980</year>;<volume>19</volume>:
<fpage>161</fpage>â<lpage>76</lpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>